The tumor microenvironment contributes to therapeutic evasion by establishing a protective niche through fibroblast-derived factors, infiltration of immunosuppressive cells, and extracellular matrix remodeling, thereby attenuating the efficacy of ALK inhibitors [76]. The gene discussed is ALK; the disease is neoplasm.